Literature DB >> 1851618

Late toxicities and complications in three-year survivors of small cell lung cancer.

F Oshita1, T Tamura, A Kojima, K Yamada, M Fukuda, K Nakagawa, Y Ohe, Y Sasaki, K Eguchi, T Shinkai.   

Abstract

123 patients with small cell lung cancer (SCLC) presented to the National Cancer Center Hospital (Tokyo) between 1978 and 1986. 22 of 71 patients with limited stage disease (LD) and none of 52 patients with extensive disease (ED) survived for 3 years. 15 of the 22 three year survivors had significant late complications. All patients received chemotherapy and either thoracic irradiation, resection or both. No prophylactic cranial irradiation was given. 4 patients developed cardiac failure, 2 with a dilated cardiomyopathy, despite the fact that no patient received over 420 mg/m2 of doxorubicin. 12 patients of the 17 who received thoracic irradiation developed radiation pneumonitis and 3 required hospitalisation for severe haemoptysis (2) or cavity formation (1). 1 patient who received nimustine developed a fatal myelodysplastic syndrome and 2 additional patients developed second primary tumours in the oesophagus (1) and stomach (1). Mild peripheral neuropathy (WHO grade 1) was persistent in 3 patients and asymptomatic azotemia (WHO grade 1) in 7. Despite advances in the treatment of SCLC there are very few asymptomatic long-term survivors.

Entities:  

Mesh:

Year:  1991        PMID: 1851618     DOI: 10.1016/0277-5379(91)90378-q

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  2 in total

Review 1.  The impact of surgery on the multidisciplinary treatment of bronchogenic small cell carcinoma (updated review including ongoing studies).

Authors:  W Theuer; O Selawry; K Karrer
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

Review 2.  Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.

Authors:  Ying-Wen Su; Ming-Chih Chang; Ming-Fu Chiang; Ruey-Kuen Hsieh
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.